These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32406275)

  • 41. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis.
    Lunder T; Zorko MS; Kolar NK; Suhodolcan AB; Marovt M; Leskovec NK; Marko PB
    Int J Dermatol; 2019 Jun; 58(6):631-641. PubMed ID: 30973647
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year.
    Yasmeen N; Sawyer LM; Malottki K; Levin LÅ; Didriksen Apol E; Jemec GB
    J Dermatolog Treat; 2022 Feb; 33(1):204-218. PubMed ID: 32202445
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice.
    Khobzey K; Liskova I; Szegedi A; Pavlovsky L; Lunder T; Kingo K; Miljković J; Péč J; Bohinc M; Hojnik M
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Mar; 26(1):11-14. PubMed ID: 28352929
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly.
    Di Lernia V; Goldust M
    Expert Opin Biol Ther; 2018 Aug; 18(8):897-903. PubMed ID: 30032682
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
    Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
    Van Voorhees AS; Stein Gold L; Lebwohl M; Strober B; Lynde C; Tyring S; Cauthen A; Sofen H; Zhang Z; Paris M; Wang Y
    J Am Acad Dermatol; 2020 Jul; 83(1):96-103. PubMed ID: 32032692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of tyrosine-kinase-2 and phosphodiesterase-4 inhibitors for scalp psoriasis: a systematic review and meta-analysis.
    Tsiogkas SG; Karamitrou EK; Grammatikopoulou MG; Zafiriou E; Bogdanos DP
    Curr Med Res Opin; 2024 Feb; 40(2):155-163. PubMed ID: 37997745
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data.
    Bagel J; Glick B; Wu JJ; Chopra I; Song X; Brouillette M; Mendelsohn A; Rozzo S; Han G
    J Med Econ; 2021; 24(1):782-791. PubMed ID: 34107834
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study.
    Li Y; Lu JJ; Zhong XY; Yu YY; Yu N; Wang Y; Yi XM; Ding YF; Shi YL
    Clin Cosmet Investig Dermatol; 2022; 15():2245-2252. PubMed ID: 36304759
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biologics switch in psoriasis.
    Wang TS; Tsai TF
    Immunotherapy; 2019 Apr; 11(6):531-541. PubMed ID: 31135243
    [No Abstract]   [Full Text] [Related]  

  • 52. Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis.
    Xu S; Gao X; Deng J; Yang J; Pan F
    J Dtsch Dermatol Ges; 2021 Jan; 19(1):47-56. PubMed ID: 33377312
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis.
    Wu JJ; Jia X; Zhao Y; Carrico J; Brodtkorb TH; Mendelsohn A; Lowry S; Feldman SR; Armstrong A
    J Dermatolog Treat; 2021 Nov; 32(7):693-700. PubMed ID: 32233828
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
    Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
    Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
    J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis.
    Reich K; Conrad C; Kristensen LE; Smith SD; Puig L; Rich P; Sapin C; Holzkaemper T; Koppelhus U; Schuster C
    J Dermatolog Treat; 2022 May; 33(3):1652-1660. PubMed ID: 33641593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biologics in the treatment of pustular psoriasis.
    Wang WM; Jin HZ
    Expert Opin Drug Saf; 2020 Aug; 19(8):969-980. PubMed ID: 32615817
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.
    Bagel J; Lynde C; Tyring S; Kricorian G; Shi Y; Klekotka P
    J Am Acad Dermatol; 2012 Jul; 67(1):86-92. PubMed ID: 22014541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis.
    Chiricozzi A; Costanzo A; Fargnoli MC; Malagoli P; Piaserico S; Amerio P; Argenziano G; Balato N; Bardazzi F; Bianchi L; Carrera CG; Conti A; Dapavo P; De Simone C; Loconsole F; Lo Schiavo A; Malara G; Musumeci ML; Parodi A; Peris K; Prignano F; Rongioletti F; Talamonti M; Potenza C
    Eur J Dermatol; 2021 Feb; 31(1):3-16. PubMed ID: 33648915
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis.
    Nast A; Jacobs A; Rosumeck S; Werner RN
    J Invest Dermatol; 2015 Nov; 135(11):2641-2648. PubMed ID: 26046458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.